Type of response to imatinib mesylate therapy by disease status at the initiation of therapy
| . | No. (%) responding . | |||
|---|---|---|---|---|
| No.patients . | Complete hematologic response . | Cytogenetic response . | ||
| Complete . | Partial . | |||
| CML phase and status | ||||
| Chronic, CHR | 1 | NA | NA | NA |
| Chronic, active | 4 | 4 (100) | — | 1 (25) |
| Accelerated, CHR | 3 | NA | 1 (33) | — |
| Accelerated, active | 12 | 10 (83) | 7 (58) | 3 (25) |
| Blastic-medullary | 7 | 3 (43) | 1 (14) | 2 (29) |
| Blastic-EMD | 1 | NA (EMD-CR) | NA | NA |
| Total | 28 | 17 of 23 (74) | 9 of 26 (35) | 6 of 26 (23) |
| 15 of 26 (58)3-150 | ||||
| Prior DLI therapy | ||||
| Yes | 13 | 9 of 11 (82) | 5 of 123-151 (42) | 3 of 12 (25) |
| No | 15 | 9 of 13 (69) | 4 of 143-152 (29) | 3 of 14 (21) |
| . | No. (%) responding . | |||
|---|---|---|---|---|
| No.patients . | Complete hematologic response . | Cytogenetic response . | ||
| Complete . | Partial . | |||
| CML phase and status | ||||
| Chronic, CHR | 1 | NA | NA | NA |
| Chronic, active | 4 | 4 (100) | — | 1 (25) |
| Accelerated, CHR | 3 | NA | 1 (33) | — |
| Accelerated, active | 12 | 10 (83) | 7 (58) | 3 (25) |
| Blastic-medullary | 7 | 3 (43) | 1 (14) | 2 (29) |
| Blastic-EMD | 1 | NA (EMD-CR) | NA | NA |
| Total | 28 | 17 of 23 (74) | 9 of 26 (35) | 6 of 26 (23) |
| 15 of 26 (58)3-150 | ||||
| Prior DLI therapy | ||||
| Yes | 13 | 9 of 11 (82) | 5 of 123-151 (42) | 3 of 12 (25) |
| No | 15 | 9 of 13 (69) | 4 of 143-152 (29) | 3 of 14 (21) |
Accelerated CHR indicates patients who were in accelerated phase (clonal evolution) but who had a normal WBC count at the start of therapy and could thus not be evaluated for achievement of CHR.
NA indicates not applicable.
This total is the sum of totals for columns “Complete” and “Partial.”
Exclude patient 17 in Table 2 (EMD).
Exclude patient 20 in Table 2 (Ph 0% at start chronic/CHR).